Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: A longitudinal, observational cohort study

Clinical Drug Investigation

Volumn 29, Issue 2, 2009, Pages 101-109

  Viganò, Alessandra ^a   Brambilla, Paolo ^b   Pattarino, Giulia ^a   Stucchi, Sara ^a   Fasan, Silvia ^a   Raimondi, Chiara ^a   Cerini, Chiara ^a   Giacomet, Vania ^a   Zuccotti, Gian V ^a   Bedogni, Giorgio ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Azienda Sanitaria Locale   (Italy)

^c Liver Research Center   (Italy)

Author keywords

Antiretrovirals, pharmacodynamics; Blood glucose, general; Children; Glucose intolerance; HIV infections; Insulin resistance

Indexed keywords

EFAVIRENZ; GLUCOSE; INDINAVIR; INSULIN; LAMIVUDINE; NELFINAVIR; RITONAVIR; STAVUDINE; TENOFOVIR;

ADOLESCENT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHILD; CLINICAL ARTICLE; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; BLOOD GLUCOSE; CHILD; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HIV-1; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; PROSPECTIVE STUDIES; PUBERTY; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149391312     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200929020-00004     Document Type: Article

References (34)

1. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999 Jul 9; 13 (10): F63-70
2. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000 Dec; 31 (6): 1467-75
3. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998 Oct 22; 12 (15): F167-73
4. Dubé MP, Edmondson-Melançon H, Qian D, et al. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2001 Jun 1; 27 (2): 130-4
5. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000 Jan 1; 23 (1): 35-43
6. Walli RK, Michl GM, Bogner JR, et al. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001 Oct 29; 6 (10): 413-21
7. Domingo P, Matías-Guiu X, Pujol RM, et al. Switching to nevirapine decreases insulin levels but does not improve sub-cutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J Infect Dis 2001 Nov 1; 184 (9): 1197-201
8. Martínez E, García-Viejo MA, Blanco JL, et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000 Nov; 31 (5): 1266-73
9. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001 May 4; 15 (7): F11-8
10. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000 Jul 7; 275 (27): 20251-4
11. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is asso-ciated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005 Sep 2; 19 (13): 1375-83
12. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007 Aug 20; 21 (13): 1739-45
13. Fleischman A, Johnsen S, Systrom DM, et al. Effects of nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007 Jun; 292 (6): E1666-73
14. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immun Defic Syndr 2005 Oct 1; 40 (2): 121-31
15. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immun Defic Syndr 2006 Aug 15; 42 (5): 562-71
16. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000 Dec 1; 25 (4): 312-21
17. De Wit S, Sabin CA, Weber R, et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care 2008 Feb 11; 31 (6): 1224-9
18. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS 2003 Jun 13; 17 (9): 1319-27
19. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics 2002 Nov; 110 (5): e56
20. Melvin AJ, Lennon S, Mohan KM, et al. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses 2001 Aug 10; 17 (12): 1117-23
21. Jaquet D, Lévine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000 Sep 29; 14 (14): 2123-8
22. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005 Oct 1; 40 (2): 161-8
23. Hadigan C, Purdy JB, Worrell C, et al. Impaired glucose toler-ance and other metabolic abnormalities in adolescents and young adults with HIV infection acquired perinatally or in childhood [abstract no. 591]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
24. Bitnun A, Sochett E, Dick PT, et al. Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005 Jan; 90 (1): 168-74
25. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000 Jun 8; (314): 1-27
26. Tanner JM. Foetus into man: physical growth from conception to maturity. Cambridge (MA): Harvard University Press, 1990
27. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26 Suppl. 1: S5-20
28. Hardin JW, Hilbe J. Generalized estimating equations. Boca Raton (FL): Chapman & Hall/CRC, 2003
29. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003 Sep; 17 (3): 305-22
30. Chu JW, Abbasi F, Beatty GW, et al. Methods for quantifying insulin resistance in human immunodeficiency virus-positive patients. Metabolism 2003 Jul; 52 (7): 858-61
31. Shikuma CM, Yang Y, Glesby MJ, et al. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr 2007 Apr 15; 44 (5): 540-50
32. Goran MI, Gower BA. Longitudinal study on pubertal insulin resistance. Diabetes 2001 Nov; 50 (11): 2444-50
33. Goran MI, Ball GD, Cruz ML. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adoles-cents. J Clin Endocrinol Metab 2003 Apr; 88 (4): 1417-27
34. Hannon TS, Rao G, Arslanian SA. Childhood obesity and type 2 diabetes mellitus. Pediatrics 2005 Aug; 116 (2): 473-80